These NCCN Guidelines for Patients® are based on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for breast cancer (version 3.2020, March 6, 2020). We support the NCCN Guidelines for Patients: Invasive Breast Cancer knowing that these tools will help equip patients with many of the educational resources and answers to questions they may seek. We endorse the NCCN Guidelines for Patients: Invasive Breast Cancer for patients seeking information about all options for breast reconstruction after cancer.
As the nation's leading organization serving the hereditary cancer community, FORCE is pleased to support the NCCN Guidelines for Patients: Invasive Breast Cancer. Sharsheret is proud to support this important resource, NCCN Guidelines for Patients: Invasive Breast Cancer. Invasive breast cancer is cancer that has spread from the milk ducts or mammary glands into the breast tissue or nearby lymph nodes.
Invasive breast cancer is breast cancer that has spread from the milk ducts or lobules into the breast tissue or a nearby lymph node. Breast cancer that has metastasized to other parts of the body is still called breast cancer.
Clinical staging of lymph nodes is staging before surgery
M (metastasis) - If cancer has spread to distant parts of the body or metastasized numbered stages. If breast cancer spreads, it often first goes to nearby lymph nodes under the arm. Breast cancer often starts in the ducts or lobules and then spreads to the surrounding tissue.
Invasive breast cancer is cancer that has grown outside the ducts or lobules into surrounding tissue. Once outside the ducts or lobules, breast cancer can spread through lymph or blood to lymph nodes or other parts of the body. A computed tomography (CT or CAT) scan uses X-rays and computer technology to take pictures of the inside of the body.
A bone scan uses a radiotracer to make pictures of the inside areas of your bone that are abnormal. An ultrasound uses high-energy sound waves to form images of the body's interior.
Biopsy
The clips stay in place and can be in your body for a period of time. A sentinel lymph node is the first lymph node to which most cancer cells from a primary tumor will spread. To find the thyroid lymph nodes, a radioactive material and other dyes are injected into the body near the breast where they travel through the lymphatics in the breast to the lymph.
In an axillary lymph node biopsy, a sample of lymph node near the armpit (axilla) is biopsied with a needle. This is to determine whether abnormal lymph nodes seen on imaging tests contain cancer cells. This is done after an ALN biopsy or SLNB shows cancer in the lymph nodes (called node positive).
Lymph node surgery
Hormone receptors
Hormone receptor-negative (HR-) breast cancer cells do not have receptors for the hormones estrogen or progesterone either. These cancer cells do not need estrogen to grow and continue to grow despite treatment to block estrogen. A sample of your tumor or blood can be used to see if the cancer cells have any specific mutations.
When cancer cells have more than a normal number of microsatellites, it is called MSI-H (microsatellite instability-high). Examples of some tumor markers in breast cancer include carcinoembryonic antigen (CEA), CA 15-3 and CA 27.29. Your healthcare provider can refer you for genetic testing to learn more about your risk of developing breast cancer or other cancers.
Denosumab and zoledronic acid are also used in those with metastatic breast cancer who have bone metastases to prevent fractures or spinal cord compression. A mutation in this gene can lead to increased growth of cancer cells and resistance to various treatments.
Because of clinical trials, doctors are finding safe and helpful ways to improve your cancer care and treatment.
Sometimes side effects of surgery, cancer or its treatment can make you not hungry or feel sick to your stomach (nausea). Some members of your care team will be with you throughout your cancer treatment, while others will be with you only part of the time. This person can help you express your feelings about your treatment to your cancer care team.
This will make it easier for you and everyone involved in your care to know who to contact with questions or concerns. If you are planning a volume shift, a larger part of the breast will need to be removed. Breasts can be reconstructed using tissue from your own body, known as 'flaps'. The flaps are taken from the abdomen, buttocks or from under the shoulder blade.
You can also reconstruct warts with tissue from the thigh, the other wart, or the genitals between the legs (vulva). A volume shift is the movement of breast tissue to fill the hole created after a lumpectomy.
Breast implants
Follow-up care
It will provide a summary of the possible long-term effects of the treatment and a list of further tests. Find out how your primary care provider will coordinate with specialists for your follow-up care. Adjuvant systemic therapy is given after surgery to kill any remaining cancer cells and help prevent the cancer from coming back.
In stage 3 breast cancer, the cancer may be large and the lymph nodes may be fixed (or immobile), or the cancer may involve the skin or chest wall. If preoperative systemic therapy is an option for you, you will undergo tests before starting treatment. These tests will determine whether your cancer can be removed with surgery (operable) or if it cannot currently be removed with surgery (inoperable).
Placing Clips - The clips are placed to help the surgeon know where to operate if the cancer resolves with preoperative therapy. If there is no residual disease after preoperative therapy or no preoperative therapy: complete up to one year of HER2-targeted therapy with trastuzumab alone or with pertuzumab. With a partial response, the tumor in the breast or lymph nodes has become smaller.
Adjuvant radiotherapy (RT) to the whole breast with or without boost to the tumor bed; and consider strong radiation to supraclavicular/. If initial tests show that the tumor cannot be removed with surgery (inoperable), you will have preoperative treatment. If the tumor did not shrink enough to be removed with surgery, then you will have more preoperative treatment.
Adjuvant therapy is based on the size of the tumor, whether cancer remains (residual disease) and if cancer is found in the lymph nodes.
BINV-14
Endocrine therapy (see Guide 20) and complete up to one year of HER2-targeted therapy with. Tamoxifen for 4.5 to 6 years, then an aromatase inhibitor for 5 years or consider tamoxifen for another 5 years (a total of 10 years on tamoxifen). For those who cannot take aromatase inhibitors or who do not want aromatase inhibitors, take tamoxifen for 5 years or consider taking tamoxifen for up to 10 years.
If no disease occurs after preoperative therapy, you will receive a maximum of one year of HER2-targeted therapy with trastuzumab alone or with pertuzumab. If the disease remains in the breast or there is cancer in the lymph nodes (node positive), you will be given ado-trastuzumab. If ado-trastuzumab emtansine is discontinued due to toxicity, you will receive trastuzumab alone or together with pertuzumab to complete one year of treatment.
If ado-trastuzumab emtansine was discontinued due to toxicity, then trastuzumab alone or with pertuzumab to complete one year of treatment. If the disease does not go away after preoperative therapy, you will have endocrine therapy and HER2- for up to one year. If the disease remains or there is cancer in the lymph nodes (node positive), you will have adotrastuzumab emtansine.
Follow-up care
In inflammatory breast cancer (IBC), cancer cells block the lymphatic vessels in the skin of the breast. Rebecca Aft, MD, PhD Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine Doreen Agnese, MD. Kelly Marcom, MD Duke Cancer Institute Jennifer Matro, MD University of Pennsylvania Abramson Cancer Center Ingrid A.
UC San Diego Moores Kanker Sentrum Karen Lisa Smith, MD, MPH Die Sidney Kimmel Omvattende Kanker Sentrum by Johns Hopkins. dukecancerinstitute.org Fox Chase Cancer Centre Philadelphia, Pennsylvania foxchase.org Huntsman Cancer Institute by die Universiteit van Utah Salt Lake City, Utah huntsmancancer.org Fred Hutchinson Cancer Research Centre/Seattle Cancer Care Alliance Seattle, Washington. moffitt.org Die Ohio State University Comprehensive Cancer Centre - James Cancer Hospital en Solove Research Institute Columbus, Ohio.
roswellpark.org Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine St.
NCCN GUIDELINES FOR PATIENTS ®
